Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Flamel Technologies S.A. FLML

Healthcare Biotechnology
"Flamel Technologies SA is a specialty pharmaceutical company engaged in drug delivery and formulation development to create safer and more efficacious pharmaceutical products to address unmet medical needs and/or reduce overall healthcare costs."

Recent & Breaking News (NDAQ:FLML)

Flamel Technologies Doses First Patient in REST-ON Phase III Trial of FT218 for Excessive Daytime Sleepiness & Cataplexy

Marketwired December 16, 2016

Flamel Technologies to Present Jefferies 2016 London Healthcare Conference

Marketwired November 9, 2016

CORRECTION - Flamel Technologies Reports Third Quarter 2016 Results

Marketwired November 7, 2016

Flamel Technologies Reports Third Quarter 2016 Results

Marketwired November 7, 2016

Flamel Technologies to Report Third Quarter 2016 Results

Marketwired October 25, 2016

Mid-Morning Market Update: Markets Mostly Higher; Verizon Posts Mixed Q3 Results

Benzinga.com  October 20, 2016

Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III Pivotal Trial of FT218

Marketwired October 6, 2016

Flamel Technologies to Present at Ladenburg Thalmann 2016 Healthcare Conference

Marketwired September 19, 2016

Flamel Technologies to Host Investor & Analyst Meeting

Marketwired September 19, 2016

Flamel Technologies Hires Vice President of Sales

Marketwired August 31, 2016

Flamel Technologies Launches Akovaz(TM)

Marketwired August 12, 2016

Flamel Technologies Announces Shareholder Approval of Cross-Border Merger

Marketwired August 12, 2016

Flamel Technologies Reports Second Quarter 2016 Results

Marketwired August 8, 2016

Flamel Technologies to Report Second Quarter 2016 Results

Marketwired July 22, 2016

Flamel Technologies to Present at Two Upcoming Investor Conferences

Marketwired June 1, 2016

Flamel Technologies Reports First Quarter 2016 Results

Marketwired May 9, 2016

Flamel Technologies to Report First Quarter 2016 Results

Marketwired May 2, 2016

Flamel Technologies Receives FDA Approval of Akovaz(TM)

Marketwired May 2, 2016

Flamel Technologies to Present at Upcoming Investor Conferences

Marketwired April 22, 2016

Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate

Marketwired March 31, 2016